- Home
- APLT vs PRTA Comparison
APLT vs PRTA Comparison
Compare APLT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- PRTA
- Stock Information
- Founded
- APLT 2016
- PRTA 2012
- Country
- APLT United States
- PRTA Ireland
- Employees
- APLT N/A
- PRTA N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- PRTA Health Care
- Exchange
- APLT Nasdaq
- PRTA Nasdaq
- Market Cap
- APLT 971.6M
- PRTA 802.8M
- IPO Year
- APLT 2019
- PRTA N/A
- Fundamental
- Price
- APLT $8.69
- PRTA $14.01
- Analyst Decision
- APLT Strong Buy
- PRTA Buy
- Analyst Count
- APLT 5
- PRTA 7
- Target Price
- APLT $12.50
- PRTA $57.67
- AVG Volume (30 Days)
- APLT 1.8M
- PRTA 476.3K
- Earning Date
- APLT 11-07-2024
- PRTA 11-12-2024
- Dividend Yield
- APLT N/A
- PRTA N/A
- EPS Growth
- APLT N/A
- PRTA N/A
- EPS
- APLT N/A
- PRTA N/A
- Revenue
- APLT N/A
- PRTA $133,350,000.00
- Revenue This Year
- APLT N/A
- PRTA $60.63
- Revenue Next Year
- APLT $3,169.03
- PRTA N/A
- P/E Ratio
- APLT N/A
- PRTA N/A
- Revenue Growth
- APLT N/A
- PRTA N/A
- 52 Week Low
- APLT $1.79
- PRTA $14.00
- 52 Week High
- APLT $10.62
- PRTA $41.55
- Technical
- Relative Strength Index (RSI)
- APLT 46.34
- PRTA 31.91
- Support Level
- APLT $9.44
- PRTA $17.27
- Resistance Level
- APLT $10.62
- PRTA $18.60
- Average True Range (ATR)
- APLT 0.62
- PRTA 1.11
- MACD
- APLT -0.13
- PRTA -0.15
- Stochastic Oscillator
- APLT 14.95
- PRTA 0.20
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).